Background : Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful analytical tool in metabolomics, but it is often hindered by the high cost and technical complexity of the machines, limiting its clinical and point-of-care applications. Recent advances in benchtop NMR technology have sought to overcome these barriers by providing more compact, affordable, and user-friendly instruments. This systematic review aims to assess the potential of benchtop NMR in clinical metabolomics, highlighting its practical advantages, current applications, and technological challenges relative to high-field systems. Methods: For this systematic review we searched Web of Science and PubMed databases to identify studies employing benchtop NMR spectroscopy in clinical and biomedical applications. The review focuses on works that evaluated metabolic profiling in human and animal disease contexts, compared benchtop and high-field performance, and utilized advanced data analysis methods, including multivariate and machine learning approaches. Results: Among the 74 records identified, 15 research articles were eligible, including 11 studies involving human biospecimens and 4 studies concerning animal samples. The selected works were published between 2018 and 2025. These studies demonstrated the potential clinical utility of low-field NMR in differentiating disease states such as tuberculosis, type 2 diabetes, neonatal sepsis, and chronic kidney disease, achieving diagnostic accuracies comparable to high-field instruments. Conclusions: Although limited by lower sensitivity and spectral resolution, benchtop NMR represents a significant step toward the democratization of NMR-based metabolomics. Continued hardware development, improved pulse sequences, and the integration of artificial intelligence for spectral processing and modeling are expected to enhance its analytical power and accelerate its clinical adoption.

Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring systemic biological therapies, such as the IL-4/IL-13 inhibitor Dupilumab, for long-term disease control. While Dupilumab is highly effective in restoring the skin barrier and reducing clinical severity, systemic complications may occur. We report a 62-year-old female with severe AD longitudinally monitored during Dupilumab treatment at baseline (T0), week 4 (T4), week 8 (T8), and week 16 (T16). Clinical assessments were performed at all visits, while microbiological, cytokine, metagenomic, and metabolomic analyses were conducted at T0, T8, and T16. The patient showed rapid clinical improvement at T4, followed by an abrupt transient worsening associated with an intercurrent S. aureus sepsis, and sustained improvement by T16, with EASI decreasing from 50.4 to 20. Despite the systemic inflammatory surge, no cutaneous relapse was documented. Multi-omics profiling highlighted a distinct immunological decoupling: while skin S. aureus load and type 2 inflammatory markers (IL-13, IL-31) progressively declined, a sharp surge in systemic pro-inflammatory cytokines (TNF-alpha) was observed at week 16, temporally associated with the septic episode. This case illustrates how longitudinal multi-omics profiling may uncover clinically silent systemic immune alterations that are not captured by conventional disease activity scores.